Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia

Current Opinion in Oncology

Volumn 27, Issue 6, 2015, Pages 532-539

  Voso, Maria Teresa ^a   Lo Coco, Francesco ^a   Fianchi, Luana ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acute myeloid leukemia; Azacitidine; Decitabine; Myelodysplastic syndromes

Indexed keywords

AZACITIDINE; DECITABINE; GUADECITABINE; HISTONE DEACETYLASE INHIBITOR; SELINEXOR; ANTINEOPLASTIC ANTIMETABOLITE; DNA METHYLTRANSFERASE; ENZYME INHIBITOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE COURSE; DISEASE FREE SURVIVAL; EPIGENETICS; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DNA METHYLATION; DRUG EFFECTS; LEUKEMIA, MYELOID, ACUTE; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; PROCEDURES;

ANTIMETABOLITES, ANTINEOPLASTIC; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EPIGENOMICS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES;

EID: 84944069525     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000231     Document Type: Review

References (37)

1. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371:2477-2487.
2. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371:2488-2498.
3. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015; 125:1367-1376.
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-232.
5. Voso MT, Niscola P, Piciocchi A, et al. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low-blast count acute myeloid leukemia. Eur J Haematol 2015. [Epub ahead of print]
6. Hwang KL, Song MK, Shin HJ, et al. Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine. Blood Res 2014; 49:234-240.
7. Falantes J, Calderón C, Márquez-Malaver FJ, et al. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with less than 10% bone marrow blasts and non unfavorable cytogenetic categories. Clin Lymphoma Myeloma Leuk 2013; 13:144-152.
8. Oshikawa G, Yoshioka K, Takahashi Y, et al. Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome. Pathol Oncol Res 2015. [Epub ahead of print]
9. Jung HA, Maeng CH, Kim M, et al. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients. Oncotarget 2015; 6:16653-16662.
10. Harel S, Cherait A, Berthon C, et al. Outcome of patients with high risk myelodysplastic syndrome (MDS) and advanced chronic myelomonocytic leukemia (CMML) treated with decitabine after azacitidine failure. Leuk Res 2015; 39:501-504.
11. Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011; 96:441-449.
12. Cabrero M, Jabbour E, Ravandi F, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up. Leuk Res 2015; 39:520-524.
13. Falantes J, García Delgadob R, Calderón-Cabreraa C, et al., for the Spanish Group of Myelodysplastic Syndromes (GESMD). Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Leuk Res 2015; 39:52-57.
14. Tseng E, Prica A, Zhang L, et al. Monthly blood transfusions decrease after four months of azacitidine. Vox Sang 2015; 109:163-167.
15. Della Porta MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Gruppo Italiano Trapianto di Midollo Osseo. Blood 2014; 123:2333-2342.
16. Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions: a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant 2015; 21:653-660.
17. Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29:1987-1996.
18. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-1803.
19. Smith BD, Beach CL, Mahmoud D, et al. Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol 2014; 3:10.
20. Ferrara F. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia? Hematol Oncol 2014; 32:1-9.
21. Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 2014; 93:1825-1838.
22. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs. conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. Blood 2015; 126:291-299.
23. Gupta N, Miller A, Gandhi S, et al. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients <60 years old. Am J Hematol 2015; 90:639-646.
24. Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma 2014; 55:1533-1537.
25. Voso MT, Santini V, Fabiani E, et al. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica 2014; 99:613-619.
26. Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. J Clin Oncol 2014; 12:1242-1249.
27. Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 2015; 90:276-281.
28. Issa JP, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 2015; 121:556-561.
29. Kirschbaum M, Gojo I, Goldberg SL, et al. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol 2014; 167:185-193.
30. Zhao WH, Zeng QC, Huang BT, et al. Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome. Leuk Res 2015; 39:424-428.
31. Silverman LR, McKenzie DR, Peterson BL, et al. Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24:3895-3903.
32. Srivastava P, Paluch BE, Matsuzaki J, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res 2014; 38:1332-1341.
33. Ranganathan P, Yu X, Santhanam R, et al. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood 2015; 125:2689-2692.
34. Stein EM, Altman JK, Collins R, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. 2014 ASH annual meeting [Abs 115].
35. Falantes J, Trujillo P, Piruat J, et al. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. Clin Lymph Myeloma Leuk 2015; 15:236-244.
36. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014; 124:2705-2712.
37. Meldi K, Qin T, Buchi F, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest 2015; 125:1857-1872.